Repurpose The Natural Compounds By Molecular Docking Of The Himalayan Region Against Glioblastoma Multiforme.
Main Article Content
Abstract
Mastishk vriddhi caused death in humans from ancient times to be also known as Glioblastoma multiforme. It is grade IV astrocytoma and appears as star-shaped glial cells in the frontal and temporal lobes of the brain. Temazolamide with radiation therapy to treat Glioblastoma currently but still not succeed completely and exhort threat as drug resistance.DYRK1A and IDH target the cell cycle and manage mitochondrial dysfunction to control oncoprotein 2-hydroxy glutarate—this study structure-based drug design method to screen natural compounds from the Himalayan region
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Abekhoukh, S. et al. (2013) ‘Dyrk1A, a serine/threonine kinase, is involved in ERK and Akt activation in the brain of hyperhomocysteinemic mice’, Molecular Neurobiology [Preprint]. Available at: https://doi.org/10.1007/s12035-012-8326-1.
Ahmad, N.H., Rahim, R.A. and Mat, I. (2010) ‘Catharanthus roseus aqueous extract is cytotoxic to jurkat leukaemic T-cells but induces the proliferation of normal peripheral blood mononuclear cells’, Tropical Life Sciences Research [Preprint].
Balaji E, V. et al. (2023) ‘In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma’, Journal of Biomolecular Structure and Dynamics [Preprint]. Available at: https://doi.org/10.1080/07391102.2023.2215884.
Bijnsdorp, I. V. et al. (2021) ‘Feasibility of phosphoproteomics to uncover oncogenic signalling in secreted extracellular vesicles using glioblastoma-EGFRVIII cells as a model’, Journal of Proteomics [Preprint]. Available at: https://doi.org/10.1016/j.jprot.2020.104076.
BIOVIA (2017) ‘Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017’, Dassault Systèmes [Preprint].
Clark, O., Yen, K. and Mellinghoff, I.K. (2016) ‘Molecular pathways: Isocitrate dehydrogenase mutations in cancer’, Clinical Cancer Research [Preprint]. Available at: https://doi.org/10.1158/1078-0432.CCR-13-1333.
Daina, A., Michielin, O. and Zoete, V. (2017) ‘SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules’, Scientific Reports [Preprint]. Available at: https://doi.org/10.1038/srep42717.
Dang, L., Yen, K. and Attar, E.C. (2016) ‘IDH mutations in cancer and progress toward development of targeted therapeutics’, Annals of Oncology [Preprint]. Available at: https://doi.org/10.1093/annonc/ mdw013.
Docking, A.J.A. et al. (1998) ‘Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function’, Journal of computational chemistry [Preprint].
Ellor, S. V., Pagano-Young, T.A. and Avgeropoulos, N.G. (2014) ‘Glioblastoma: Background, standard treatment paradigms, and supportive care considerations’, Journal of Law, Medicine and Ethics [Preprint]. Available at: https://doi.org/10.1111/jlme.12133.
Hunter, A.D. (1997) ‘ACD/ChemSketch 1.0 (freeware); ACD/ChemSketch 2.0 and its Tautomers, Dictionary, and 3D Plug-ins; ACD/HNMR 2.0; ACD/CNMR 2.0’, Journal of Chemical Education [Preprint]. Available at: https://doi.org/10.1021/ed074p905.
Laplante, M. and Sabatini, D.M. (2012) ‘MTOR signaling in growth control and disease’, Cell [Preprint]. Available at: https://doi.org/10.1016/j.cell.2012.03.017.
Li, Y. ling et al. (2019) ‘DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291’, Journal of Cellular and Molecular Medicine [Preprint]. Available at: https://doi.org/10.1111/jcmm.14609.
Luna, J. et al. (2019) ‘DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth’, Gut [Preprint]. Available at: https://doi.org/10.1136/gutjnl-2018-316128.
Ma, D.J. et al. (2015) ‘A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K’, Neuro-Oncology [Preprint]. Available at: https://doi.org/10.1093/neuonc/nou328.
Morris, G.M. et al. (2009) ‘Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility’, Journal of Computational Chemistry [Preprint]. Available at: https://doi.org/10.1002/jcc.21256.
O’Boyle, N.M. et al. (2011) ‘Open Babel: An Open chemical toolbox’, Journal of Cheminformatics [Preprint]. Available at: https://doi.org/10.1186/1758-2946-3-33.
Ostrom, Q.T. et al. (2014) ‘The epidemiology of glioma in adults: A state of the science review’, Neuro-Oncology [Preprint]. Available at: https://doi.org/10.1093/neuonc/nou087.
Ostrom, Q.T. et al. (2015) ‘CBTRUS statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012’, Neuro-Oncology [Preprint]. Available at: https://doi.org/10.1093/neuonc/nov189.
Ramamoorthy, M.D. et al. (2018) ‘Reserpine Induces Apoptosis and Cell Cycle Arrest in Hormone Independent Prostate Cancer Cells through Mitochondrial Membrane Potential Failure’, Anti-Cancer Agents in Medicinal Chemistry [Preprint]. Available at: https://doi.org/10.2174/ 18715206186 66180 209152215.
Tazarki, H. et al. (2019) ‘New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis’, European Journal of Medicinal Chemistry [Preprint]. Available at: https://doi.org/10.1016/j.ejmech.2019.01.052.
Thakkar, J.P. et al. (2014) ‘Epidemiologic and molecular prognostic review of glioblastoma’, Cancer Epidemiology Biomarkers and Prevention [Preprint]. Available at: https://doi.org/10.1158/1055-9965.EPI-14-0275.
Voelxen, N.F. et al. (2016) ‘Quantitative imaging of D-2-hydroxyglutarate in selected histological tissue areas by a novel bioluminescence technique’, Frontiers in Oncology [Preprint]. Available at: https://doi.org/10.3389/fonc.2016.00046.
Wang, P. et al. (2017) ‘Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D’, Scientific Reports [Preprint]. Available at: https://doi.org/10.1038/s41598-017-07655-1.
Wang, P., Zhao, J. and Sun, X. (2021) ‘DYRK1A phosphorylates MEF2D and decreases its transcriptional activity’, Journal of Cellular and Molecular Medicine [Preprint]. Available at: https://doi.org/10.1111/jcmm.16505.
Yan, H. et al. (2009) ‘IDH1 and IDH2 Mutations in Gliomas ’, New England Journal of Medicine [Preprint]. Available at: https://doi.org/10.1056/nejmoa0808710.
Yang, H. et al. (2012) ‘IDH1 and IDH2 mutations in tumorigenesis: Mechanistic insights and clinical perspectives’, Clinical Cancer Research [Preprint]. Available at: https://doi.org/10.1158/1078-0432.CCR-12-1773